Rankings
▼
Calendar
CTMX FY 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
FY 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$53M
+42.5% YoY
Gross Profit
$53M
100.0% margin
Operating Income
-$101M
-190.6% margin
Net Income
-$99M
-186.8% margin
EPS (Diluted)
$-1.48
Cash Flow
Operating Cash Flow
-$111M
Free Cash Flow
-$113M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$261M
Total Liabilities
$347M
Stockholders' Equity
-$86M
Cash & Equivalents
$194M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$53M
$37M
+42.5%
Gross Profit
$53M
$37M
+42.5%
Operating Income
-$101M
-$116M
+12.7%
Net Income
-$99M
-$116M
+14.3%
← Q4 2021
All Quarters
Q1 2022 →